FDA clears PicoWay picosecond laser for pigmented lesion treatment

Syneron Medical Ltd. announced that the FDA has cleared its PicoWay picosecond laser for treating pigmented lesions.

PicoWay, which incorporates picosecond pulse duration in dual wavelengths of 532 nm and 1,064 nm to generate ultra-short pulse and very high peak laser energy power on the skin, had received FDA clearance for tattoo removal in November 2014, according to the release. It was launched in the late fourth quarter of 2014 in the United States.

“The expansion of PicoWay’s FDA clearance to include pigmented lesions further enhances the utility of the system, allowing practitioners to offer this next-generation technology for more of their pigment-related procedures,” Amit Meridor, CEO of Syneron Medical, said in the release.

Syneron also announced that Health Canada has cleared the PicoWay picosecond laser for treating pigmented lesions and all colors of tattoo removal. The launch of PicoWay in Canada will begin in the second quarter of 2015, the release stated.

“Based on the strong early reception to PicoWay, we believe we are well positioned to drive adoption in Canada based on our unique PicoWay technology, strong Candela brand and broad existing customer base,” William Griffling, CEO of Syneron Candela North America, said in the release.

Reference: www.syneron.com